



**Vaccines and Global Health: The Week in Review**  
**16 December 2023 :: Issue 731**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

***Editor's Note:***

***Vaccine and Global Health: The Week in Review will resume publication on 06 January 2024.***

## ***Milestones, Perspectives***



### **Measles**

#### **[Measles cases in Europe and Central Asia skyrocket by 3000 per cent this year compared to last](#)**

*UNICEF warns that the increase in measles cases is attributable to a backsliding of immunisation coverage among children across the region*

GENEVA, 14 December 2023 – There have been **30,601 confirmed cases of measles in Europe and Central Asia between January and 5 December 2023, up from 909 throughout 2022**, marking a 3266 per cent increase in cases of the vaccine-preventable disease, warns UNICEF.

Data also point to a more recent worsening trend as the rate of measles cases in Europe and Central Asia nearly doubled between October and November 2023. Cases in the region are expected to rise further due to gaps in immunity.

**“There is no clearer sign of a breakdown in immunisation coverage than an increase in cases of measles.** Such a dramatic increase requires urgent attention and public health measures to protect children from this dangerous and deadly disease,” said Regina De Dominicis, UNICEF Regional Director for Europe and Central Asia...

The highest rate of measles cases is reported in Kazakhstan with 69 cases per 100,000 population, amounting to 13,254 cases, according to latest available data. Kyrgyzstan has the second highest rate of measles cases with 58 cases per 100,000 population, amounting to 3,811 cases. Romania, which announced last week a national measles outbreak, has a reported rate of 9.6 cases per 100,000, amount to 1,855 cases...

**Latest data show that an estimated 931,000 children in Europe and Central Asia missed out entirely or partially on routine immunization from 2019 to 2021.** In Europe and Central Asia, the immunisation rate of the first dose against measles dropped from 96 per cent in 2019 to 93 per cent in 2022. As these children pass the age when vaccines are routinely given, it requires a dedicated effort to ensure that they catch up with their vaccinations.

#### **To reach every child, UNICEF is urging countries across the region to:**

- Urgently identify and reach all children, especially those who have missed vaccinations.
- Strengthen demand for vaccines, including by building confidence.
- Prioritise funding to immunization services and primary health care.
- Build resilient health systems through investment in health workers, innovation and local manufacturing.



#### **[WHO’s Science Council issues report on mRNA vaccine technology](#)**

13 December 2023 Departmental news

Prompted by the life-saving impact of messenger ribonucleic acid (mRNA) vaccines during the COVID-19 pandemic, the World Health Organization's (WHO) Science Council has released **a report reviewing the potential benefits and limitations of mRNA vaccine technology. The report conveys the importance of research and development (R&D) efforts to COVID-19 mRNA vaccines and outlines challenges of inequitable access.**

The success of mRNA COVID-19 vaccines resulted from decades of investment in basic science exploring chemical modifications of – and immune responses to – RNA, with their potential applications for HIV, respiratory syncytial virus (RSV), severe acute respiratory syndrome (SARS), and cancer therapeutics and vaccines. Other key factors included thousands of people enthusiastically volunteering to participate in clinical trials, collaborations between researchers, and unprecedented levels of funding.

**However, the benefits of the mRNA COVID-19 vaccines were not distributed equally globally, with insufficient research and development capacity, intellectual property barriers and ultra-cold-chain requirements as well as high costs for low- and middle-income countries.**

"Unlocking the potential of mRNA technology beyond COVID-19 vaccines will require robust research to address limitations head-on," said Professor Harold Varmus, Chair of the WHO Science Council, a Nobel Laureate and former Director of the U.S. National Institutes of Health. "To improve mRNA vaccine technology, **future research should seek to develop more temperature-stable vaccines, increase how long protection lasts, and ensure effectiveness against a diverse range of strains and variants.**"

**The report recommends a framework to assess the value of mRNA technology in developing vaccines and therapeutics against other infectious diseases.** A framework could also help establish the technology's potential role in addressing cancer and autoimmune diseases. To inform such a framework, the report maps out the clinical trial status of mRNA vaccines in the most advanced stages of development.

While the COVID-19 vaccines are the only safe and efficacious preventive mRNA vaccines developed and approved for human use to date, mRNA vaccines against cytomegalovirus (a common virus that can threaten babies and those with a weakened immune system), influenza A and B, and RSV are in Phase 3 trials. There is also on-going discovery work in tuberculosis, malaria, HIV as well as noncommunicable diseases.

The report also calls for further research to address the potential of this technology as well as its limitations. Improving the stability of mRNA vaccines at higher temperatures should be a key target of investment and research efforts...

"To maximise the impact of mRNA technologies, it's vital to promote and strengthen research, going country by country, so every region has a dynamic and sustained scientific, research and development ecosystem," said Dr Jeremy Farrar, WHO's Chief Scientist. "Coupled with investment and a commitment to equitable access, a more diverse global research ecosystem will better address communicable and noncommunicable diseases and improve health outcomes with new safe and effective mRNA vaccines and potentially therapeutics for all."

The report also underscores the importance of building trust, and improved communication around mRNA technologies to limit vaccine hesitancy and misinformation and improve current and future vaccine uptake.

## [Potential benefits and limitations of mRNA technology for vaccine research and development for infectious diseases and virus-induced cancers](#)

Report of the WHO Science Council

13 December 2023 | Report

PDF: <https://iris.who.int/bitstream/handle/10665/375031/9789240084551-eng.pdf?sequence=1>

### Box 3: Key factors influencing access to mRNA COVID-19 vaccines in LMICs

- 1. Affordability:** Several LMICs could not afford to purchase COVID-19 mRNA vaccines because of the costs involved in purchasing doses of vaccine and injury insurance (required to avoid manufacturer's liability), and in setting up storage and distribution. With only two companies producing and selling mRNA vaccines, the lack of competition created no incentives for manufacturers to lower prices.
- 2. Financial status:** In the early stages of the COVID-19 vaccine rollout, many LMICs were not at the front of the queue for obtaining vaccines from pharmaceutical companies, owing to their poor buying power in this sector.
- 3. Market exclusion:** mRNA vaccine manufacturers unilaterally determined which countries would be allowed to license and market their vaccines. In the first 3 years of the COVID-19 pandemic, one manufacturer had not sought regulatory approval for its mRNA vaccine in any country in Africa, effectively precluding countries on that continent from purchasing their vaccine directly.
- 4. Vaccine testing:** Many LMICs have little prospect of being involved in vaccine R&D (including clinical trials of mRNA vaccines) because of their poorly developed clinical trial infrastructure. Some pharmaceutical companies, for instance, tested their mRNA vaccines entirely in the USA.
- 5. Access to intellectual property (IP):** Those LMICs that did have vaccine-manufacturing capabilities were not able to secure access to mRNA vaccine IP and production expertise for local manufacture of vaccines. Government agencies that funded the research that led to the IP did not stipulate or enforce sharing of IP under exceptional circumstances (e.g., a pandemic). Lack of IP access contributed – either directly or indirectly – to LMICs having limited access to mRNA vaccines.
- 6. Low production capacities in LMICs:** Without access to IP and manufacturing expertise, even those LMICs that have vaccine production capability could not produce mRNA vaccines locally. Although some LMICs produce large quantities of low-cost generic medications for AIDS treatment under voluntary or compulsory licenses, the manufacturers of mRNA vaccines chose not to provide voluntary licenses for LMICs. This effectively precluded local production of mRNA vaccines in LMICs.
- 7. Cold storage:** The low temperature cold storage requirements of mRNA vaccines presented a significant challenge for vaccine storage and distribution in many LMICs.
- 8. Multidose vials:** Since mRNA vaccines are provided in multidose vials, there was significant wastage during the COVID-19 pandemic when the number of people awaiting vaccination did not match the doses available. This wastage increased the cost per dose used and affordability.



### Featured Journal Content

#### Lancet Global Health

Jan 2024 Volume 12 Number 1 e1-e169

*Comment*

**[World Society for Pediatric Infectious Diseases calls for action to ensure fair prices for vaccines](#)**

Fiona M Russell, et al. on behalf of the World Society of Pediatric Infectious Diseases

... The COVID-19 pandemic has imposed tremendous economic and social challenges worldwide, and concerns over vaccine access and affordability are rising. The scientific community has learned much on vaccine development during the pandemic, but there remain profound and widening gaps for equitable vaccine access.

**Despite the lifesaving potential of the new respiratory syncytial virus vaccine for infants or through maternal vaccination in low-income countries, it is unlikely that these children will be protected for many years. Vaccine price should not be a barrier to the introduction or sustainability of immunisation programmes.**

Therefore, **the World Society for Pediatric Infectious Diseases calls for fair pricing for all vaccines to ensure that they are global public goods.** We ask governments and international organisations to act urgently to protect the lives of present and future generations via global, equitable access to affordable vaccines through a comprehensive approach (panel).

*Panel*

**Recommended actions by stakeholders for achieving fair vaccine prices for low-income and middle-income countries (LMICs)**

*Pharmaceutical companies*

- Commit to fair, equitable pricing strategies for vaccines, considering the socioeconomic context of all LMICs, and publish pricing by income status of countries
- Facilitate technology transfer and knowledge sharing to enable local production, local fill and finish technology, and reduce dependence on imports

*Governments and international organisations*

- Negotiate affordable pricing structures en bloc with regional states and pharmaceutical companies, promoting transparency and fair competition, and commit to publishing pricing by income status
- Explore alternative procurement strategies and promote regional cooperation and support efforts, such as the Pan American Health Organization's Revolving Fund to Access Vaccines and UNICEF's Pacific Vaccine Independence Initiative
- Support technology transfer and capacity-building initiatives to enhance local vaccine production, such as the WHO-supported mRNA technology hub in South Africa

*Research and development funders*

- Increase investments in research and development of vaccines, specifically targeting diseases prevalent in LMICs
- Encourage partnerships between academic institutions, pharmaceutical companies, and international organisations to foster vaccine research and innovation, and improve affordability

*Global health initiatives*

- Strengthen international collaborations to address vaccine inequity, and include all countries with low availability of public health funds irrespective of World Bank income classifications
- Advocate for policies and mechanisms that promote equitable vaccine access, including flexibilities

.....

.....

## Featured Journal Content

### Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 16 Dec 2023]

*Latest Articles [Selected]*

*Open Access Review*

#### [The Governance of Childhood Vaccination Services in Crisis Settings: A Scoping Review](#)

by [Nada Abdelmagid](#), et al.

Vaccines 2023, 11(12), 1853; <https://doi.org/10.3390/vaccines11121853> - 14 Dec 2023

*Abstract*

The persistence of inadequate vaccination in crisis-affected settings raises concerns about decision making regarding vaccine selection, timing, location, and recipients. This review aims to describe the key features of childhood vaccination intervention design and planning in crisis-affected settings and investigate how the governance of childhood vaccination is defined, understood, and practised. We performed a scoping review of 193 peer-reviewed articles and grey literature on vaccination governance and service design and planning. We focused on 41 crises between 2010 and 2021.

Following screening and data extraction, our analysis involved descriptive statistics and applying the governance analysis framework to code text excerpts, employing deductive and inductive approaches. Most documents related to active outbreaks in conflict-affected settings and to the mass delivery of polio, cholera, and measles vaccines. Information on vaccination modalities, target populations, vaccine sources, and funding was limited. We found various interpretations of governance, often implying hierarchical authority and regulation.

**Analysis of governance arrangements suggests a multi-actor yet fragmented governance structure, with inequitable actor participation, ineffective actor collaboration, and a lack of a shared strategic vision due to competing priorities and accountabilities.** Better documentation of vaccination efforts during emergencies, including vaccination decision making, governance, and planning, is needed. We recommend empirical research within decision-making spaces.

.....

.....

## Featured Journal Content

### Health Policy and Planning

Volume 38, Issue 10, December 2023

<https://academic.oup.com/heapol/issue/38/10>

*Reviews*

#### [A scoping review on integrated health campaigns for immunization in low- and middle-income countries](#)

Syeda Tahmina Ahmed and others

Health Policy and Planning, Volume 38, Issue 10, December 2023, Pages 1198–1224,

<https://doi.org/10.1093/heapol/czad082>

*Abstract*

Health campaign integration is a key implementation strategy outlined by the World Health Organization to achieve universal health coverage. **This scoping review synthesizes the evidence on Integrated Health Campaigns (IHC) in the field of immunization in low- and middle-income countries (LMICs) regarding the most common strategies, facilitators and barriers.** Four reviewers followed a systematic approach to identify, screen and analyse relevant articles. The team used three search engines (PubMed, Scopus and Google Scholar) to



identify peer-reviewed journal articles as well as select institutional websites for grey literature publications.

Full-text articles using any study design and across any time frame were included. Data were extracted following a predefined matrix, analysed deductively and presented in a narrative synthesis. Thirty articles (20 academic and 10 grey) were included in the final review. All studies included identified IHCs as effective when planning or implementation is integrated.

**The common strategies were:**

- using resources efficiently in remote locations;
- using national immunization days to maximize impact; targeting specific age groups by selecting intervention sites that are frequented by that age group; building community ownership over the integrated program; and
- integrating programs that already share common elements.

**The key facilitators were:**

- closing the gap between services and communities;
- planning, coordination and resource management both before and during integration;
- cost-effectiveness; and
- utilization of pre-existing infrastructure.

The common barriers included seemingly optimized initial cost to appear feasible only in the short term and additional responsibilities on the field staff. This review finds IHCs a common practice in immunization and identifies gaps in evidence on evaluation; indicating the need for additional research. Strong evidence accounts IHCs to increase coverage, improve community acceptance of health services and strengthen the community models of health service delivery.



**Polio – PHEIC**

**Polio this week as of 06 Dec 2023 - GPEI**

*Headlines [Selected]*

:: The WHO Executive Board (EB) is scheduled to take place on 22-27 January 2024, and one of the topics that will be discussed by Member States is the global effort to eradicate polio and to ensure that polio investments are sustained to build strong, equitable and resilient health systems. To this effect, the Secretariat has prepared two reports which will inform Member State discussions, namely on polio eradication and on polio transition planning and post-certification. On polio eradication, the report provides an update on work towards Goals 1 and 2 of the Polio Eradication Strategy 2022–2026. Specifically, it provides information on interrupting all wild poliovirus transmission in countries where the virus is endemic, stopping the transmission of circulating vaccine-derived poliovirus and preventing outbreaks in non-endemic countries, and the current financing situation. On transition and post-certification, the report outlines the post-2023 strategic framework, building on lessons-learned from the implementation of the 2018-2023 Strategic Action Plan. Specifically, it highlights the changes that are foreseen to strengthen ownership and accountability, monitoring and evaluation, as well as actions tailored to country context.

***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Chad: one circulating vaccine-derived poliovirus type 2 (cVDPV2) case

- Democratic Republic of the Congo: four vaccine-derived poliovirus type 1 (cVDPV1) case and one cVDPV2 case
- Guinea: eight cVDPV2 cases
- Madagascar: one cVDPV1 case
- Mali: three cVDPV2-positive environmental samples
- Nigeria: two cVDPV2 cases and two cVDPV2-positive environmental samples
- Tanzania: one cVDPV2-positive environmental sample



## Coronavirus [COVID-19]

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

### Numbers at a glance

*Last update: 13 Dec 2023*

**Confirmed cases** :: 772 386 069

**Confirmed deaths** :: 6 987 222

**Vaccine doses administered** :: 13 595 721 080



### *Our World in Data*

[Coronavirus \(COVID-19\) Vaccinations](#) [Accessed 16 Dec 2023]

:: [70.6%](#) of the world population has received at least one dose of a COVID-19 vaccine.

:: [13.53 billion doses](#) have been administered globally, and [4,341](#) are now administered each day.

:: [32.9%](#) of people in low-income countries have received at least one dose.



### **Contents** [*click to move among sections*]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)



### **WHO & Regional Offices** [to 16 Dec 2023]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

17 December 2023 Statement

[WHO delivers health supplies to Al-Shifa Hospital, appeals for continued access to address urgent needs in north Gaza](#)

15 December 2023 News release

[WHO officially recognizes noma as a neglected tropical disease](#)

13 December 2023 Statement

[Statement on the antigen composition of COVID-19 vaccines](#)



13 December 2023 Departmental news

[WHO's Science Council issues report on mRNA vaccine technology](#)

13 December 2023 Departmental news

[Parliamentarians Empowering Global Health: IPU-WHO collaboration](#)

12 December 2023 News release

[Universal Health Coverage Day 2023 focuses on building resilience of health systems](#)

12 December 2023 Statement

[WHO calls for protection of humanitarian space in Gaza following serious incidents in high-risk mission to transfer patients, deliver health supplies](#)

12 December 2023 Departmental news

[New evidence on cervical cancer screening and treatment for women living with HIV](#)

11 December 2023 Departmental news

[Health service quality must be a priority, not an afterthought: New Collection on quality of care](#)

11 December 2023 Departmental news

[WHO calls on governments for urgent action to invest in Universal Health Coverage](#)

11 December 2023 Departmental news

[New Technical Advisory Group on Embedding Ethics in Health and Climate Change Policy \(TAG-Ethics & Climate Health\)](#)

10 December 2023 News release

[WHO's Executive Board adopts resolution on access for life-saving aid into Gaza and respect for laws of war](#)

10 December 2023 News release

[Financing, stages of alert for potential pandemics among the issues debated in sixth meeting of WGIHR](#)

10 December 2023 Departmental news

[The Quadripartite launches a guide to support countries implement One Health approach](#)

.....

### **WHO Regional Offices**

*Selected Press Releases, Announcements*

#### **WHO African Region**

:: 14 December 2023

[Senegal, WHO launch regional emergency hub to bolster Africa's response to health crises](#)

:: 11 December 2023

[Five African countries report anthrax outbreaks, over 1100 cases recorded](#)

#### **WHO Region of the Americas** PAHO

:: [PAHO Director highlights efforts of the Americas to recover public health gains lost during the pandemic](#)

Washington, DC, 12 December 2023 (PAHO)- On the occasion of Universal Health Day (also called Universal Health Coverage Day), Pan American Health Organization (PAHO) Director, Dr. Jarbas Barbosa, highlighted the efforts made by countries of the Americas to recover public health gains lost due to the COVID-19 pandemic. These efforts include...

### **WHO South-East Asia Region SEARO**

:: 11 December 2023 Statement

[International Universal Health Coverage Day: Health for All - Now More than Ever](#)

### **WHO European Region EURO**

:: 16 December 2023 News release

[WHO and the Ministry of Health of Ukraine sign a Biennial Collaborative Agreement to enhance partnership and strengthen health system resilience for 2024–2025](#)

:: 15 December 2023 News release

[Respiratory infectious diseases on the rise across WHO European Region](#)

:: 14 December 2023 News release

[A 30-fold rise of measles cases in 2023 in the WHO European Region warrants urgent action](#)

### **WHO Eastern Mediterranean Region EMRO**

:: [WHO calls for protection of humanitarian space in Gaza following serious incidents in high-risk mission to transfer patients, deliver health supplies](#)

12 December 2023 –

### **WHO Western Pacific Region**

*No new digest content identified.*

.....

### **WHO - Emergency situation reports**

13 December 2023

[WHO's Operational Update on Health Emergencies - November 2023](#)

.....

### **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new DONs identified.*

.....

### **Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 98, No. 50, pp. 653–666 15 December 2023

<https://iris.who.int/bitstream/handle/10665/375068/WER9850-eng-fre.pdf>

653 WHO's Health Emergencies Programme: acute emergencies monthly summary– November 2023

657 Progress in monitoring immunization safety – worldwide, 2020–2022

665 Monthly report on dracunculiasis cases, January – October 2023

.....

## **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

13 December 2023

[Potential benefits and limitations of mRNA technology for vaccine research and development for infectious...](#)

*No abstract*

11 December 2023

[Future surveillance for epidemic and pandemic diseases](#)

*Overview*

Surveillance is a pillar of the public health response to epidemics and pandemics. Yet, gaps in surveillance, from the local to the global, continue to leave the world vulnerable to infectious hazards. To address these vulnerabilities, the health emergency preparedness, response, and resilience (HEPR) architecture calls for a new approach to future surveillance - collaborative surveillance - that aligns traditional tactics with new initiatives to safeguard health for all.

This report reflects the input and advice on future surveillance of leading experts with different skills, worldviews and experiences who share a commitment to better prepare for future infectious hazards. It charts a course towards future surveillance and collaborative action.

.....  
.....

## **USA – HHS, FDA, CDC**

### **HHS**

*News*

[Guiding Principles Help Healthcare Community Address Potential Bias Resulting from Algorithms](#)

December 15, 2023 News Release

[FACT SHEET: Biden-Harris Administration Announces Voluntary Commitments from Leading Healthcare Companies to Harness the Potential and Manage the Risks Posed by AI](#)

December 14, 2023 News Release

### **FDA**

*Press Announcements*

December 12, 2023 - [FDA Creates New Advisory Committee for Evaluation of Genetic Metabolic Disease Treatments](#)

December 8, 2023 - [FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease](#)

### **FDA VRBPAC**

*Advisory Committee Calendar*

*No new meetings scheduled.*

**CDC/ACIP [U.S.]** [to 16 Dec 2023]

<http://www.cdc.gov/media/index.html>

*Latest News Releases*

*No new digest content identified.*

## **ACIP Meetings**

*Next ACIP Meeting*

*No new meetings scheduled.*

## **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2023.html>

**December 15, 2023 / No. 50**

[PDF of this issue](#)

Notes from the Field: Transmission of Mpox to Nonsexual Close Contacts — Two U.S. Jurisdictions, May 1–July 31, 2022

.....  
.....

## **Europe**

### **European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

#### **First gene editing therapy to treat beta thalassemia and severe sickle cell disease**

EMA has recommended approval of the first medicine using CRISPR/Cas9, a novel gene-editing technology. Casgevy (exagamglogene autotemcel) is indicated for the treatment of transfusion-dependent beta thalassemia and severe sickle cell disease in patients 12 years of age and older for whom haematopoietic stem cell transplantation is appropriate and a...

15 December 2023

#### **Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023**

EMA's human medicines committee (CHMP) recommended seven medicines for approval at its December 2023 meeting.

15 December 2023

#### **First version of the Union list of critical medicines agreed to help avoid potential shortages in the EU**

The first version of the Union list of critical medicines contains more than 200 active substances of medicines for human use considered critical for healthcare systems across the EU / EEA, for which continuity of supply is a priority and shortages should be avoided.

12 December 2023

.....

### **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

#### **Acute respiratory infections in the EU/EEA: epidemiological update and current public health recommendations**

Epidemiological update - 15 Dec 2023

#### **Public health action needed to mitigate the impact of respiratory pathogens for 2023-24 winter season in Europe**

News - 15 Dec 2023

**[ECDC assesses EU/EEA zoonotic avian flu preparedness and issues investigation protocol](#)**

News - 14 Dec 2023

.....  
.....

**Africa CDC** [to 16 Dec 2023]

<http://www.africacdc.org/>

*Press Releases, Statements [Selected]  
Statement*

**[Africa CDC YPC2023: Keynote speech from the Guest of Honor, H.E. Mrs. Monica Geingos, First Lady of the Republic of Namibia](#)**

13 December 2023

.....  
.....

**China CDC**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 16 Dec 2023]

<http://en.nhc.gov.cn/>

*News*

**[Chinese health authorities issue rules on reporting emergencies](#)**

Updated: 2023-12-13 | Xinhua

BEIJING -- China's National Health Commission has released a set of response protocol for dealing with medical emergencies.

The document, effective on a trial basis, outlined the responsibilities of relevant departments in identifying, reporting and responding to emergencies.

In the event of a major emergency involving five or more cases of death or severe medical conditions, health authorities in provincial-level regions should report the situation to the NHC within two hours of being informed of it, according to the document.

The NHC has urged regional health authorities to improve their emergency response in accordance with the protocol to reduce casualties in such events and better protect the safety and well-being of the people.

**National Medical Products Administration – PRC** [to 16 Dec 2023]

<http://english.nmpa.gov.cn/>

*News*

**[China sees decline in child respiratory cases at medical facilities](#)**

2023-12-11

China has recorded a fluctuating decrease in the overall diagnosis and treatment volume of pediatric respiratory diseases at its secondary and higher-level medical institutions nationwide, the Chinese health authority said Sunday.

**China CDC Weekly Reports: Current Volume (5)**

2023-12-15 / No. 50 ***EVOLVING PATTERNS OF MORTALITY ISSUE***

[View PDF of this issue](#)

- [Preplanned Studies: Changing Patterns in Digestive Diseases Mortality in Urban and Rural Areas — China, 1987–2021](#)
- [Preplanned Studies: Changing Patterns of Mortality in Diabetes Mellitus Among Older Adults — China, 1987–2021](#)
- [Preplanned Studies: Urban-Rural Disparity in Mortality Patterns of Respiratory Diseases Among Older Adults — China, 1987–2021](#)
- [Commentary: Transitions in Chronic Disease Mortality in China: Evidence and Implications](#)



***Contents [click to move among sections]***

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)



***Organization Announcements***

**Paul G. Allen Frontiers Group** [to 16 Dec 2023]

<https://alleninstitute.org/news-press/>

*News*

*Featured*

[\*\*Scientists unveil first complete cellular map of adult mouse brain\*\*](#)

12.13.2023

High-resolution atlas charts neural neighborhoods for more than 5,300 cell types

**BMGF - Gates Foundation** [to 16 Dec 2023]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases and Statements*

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 16 Dec 2023]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 16 Dec 2023]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 16 Dec 2023]

<http://cepi.net/>

*Latest News*

**[CEPI and PATH strengthen partnership to accelerate development of vaccines against diseases with epidemic or pandemic potential](#)**

Renewed collaboration aims to accelerate the rapid development of vaccines against emerging infectious diseases, and in support of CEPI's 100 Days Mission.

14 Dec 2023

**[CEPI supports novel mRNA vaccine development in Korea to protect against future Disease X](#)**

Novel self-amplifying design has the potential to reduce dosage and cost of vaccines, supporting rapid global rollout in response to an emerging infectious disease outbreak.

12 Dec 2023

**[The Viral Most Wanted: The Coronaviruses](#)**

Seven members of the Coronavirus family are already known to infect people, often with deadly consequences. Disease investigators fear that more new and dangerous Coronaviruses could spill over at any time.

11 Dec 202

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 16 Dec 2023]

<https://cioms.ch/>

*News; Publications; Events*

**[CIOMS Working Group report on Good Governance Practice in Research Institutions now published](#)**

The aim of this report is to help research institutions better fulfil their responsibilities in terms of protecting human research participants and their communities, involving and engaging them in the research processes, and guaranteeing the pertinence and quality of research while making the best use of available resources.

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 16 Dec 2023]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 16 Dec 2023]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 16 Dec 2023]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS,*



*tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

15 December 2023

[\*\*EMA recommends arpraziquantel for treatment of schistosomiasis in preschool-aged children\*\*](#)

15 December 2023

[\*\*EMA gives positive opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness \(rhodesiense\) found in East and Southern Africa\*\*](#)

**Emory Vaccine Center** [to 16 Dec 2023]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 16 Dec 2023]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Evidence Aid** [to 16 Dec 2023]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*Resources [Selected]*

[\*\*Antimicrobial resistance among migrants in Europe\*\*](#)

Added December 12, 2023

[\*\*Effectiveness and cost-effectiveness of screening for and vaccination against hepatitis B virus among migrants in the EU/EEA\*\*](#)

Added December 11, 2023

[\*\*Applications and limitations of the concept of 'avoidable mortality' among immigrant groups in Europe\*\*](#)

Added December 10, 2023

**Fondation Merieux** [to 16 Dec 2023]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 16 Dec 2024]

<https://www.gavi.org/>

*News Releases*

11 December 2023

[\*\*Gavi and Alliance partners renew support for immunisation in Mozambique\*\*](#)

Maputo, 11 December 2023 – A high-level mission comprising Gavi, the Vaccine Alliance, the World Health Organization (WHO), United Nations Children’s Fund (UNICEF), Bill & Melinda Gates Foundation and World Bank is scheduled to visit the Republic of Mozambique from 10 December, aiming to renew political commitment towards recovery and strengthening of routine immunisation...

**GE2P2 Global Foundation** [to 16 Dec 2023]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – December 2023](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 24 Oct 2023 – Issue 09](#)

**GHIT Fund** [to 16 Dec 2023]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

December 14, 2023

**[Investment of Approximately USD 8.8 Million for New Drug Development against Malaria in Partners including Marubeni and Eisai](#)**

**Global Fund** [to 16 Dec 2023].

<https://www.theglobalfund.org/en/news/>

*News & Stories*

03 December 2023

**[The Global Fund Applauds Ireland’s Additional Pledge, Bringing Total Contribution to €65.75 Million](#)**

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) commends Ireland’s additional €750,000 pledge, bringing the Republic’s total contribution to €65.75 million for the upcoming three-year period.

03 December 2023

**[Reaching the Last Mile Welcomes Collective Commitment to Boost Support to Community Health Workers](#)**

Reaching the Last Mile – a portfolio of global health programs, investments, and initiatives working to end preventable diseases that affect the world’s most vulnerable communities– welcomes the commitment made by a coalition of partners to accelerat...

02 December 2023

**[The Global Fund to Spend 70% of Its Funding in Most Climate-vulnerable Countries](#)**

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) announced during the World Climate Summit at COP28 in Dubai that more than 70% of its funding – over US\$9 billion over the next three years – will be spent in the 50 most clima...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 16 Dec 2023]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 16 Dec 2023]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 16 Dec 2023]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 16 Dec 2023]

<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 16 Dec 2023]

<https://www.iavi.org/>

*No new digest content identified.*

**INSERM** [to 16 Dec 2023]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use** [to 16 Dec 2023]

<https://www.ich.org/page/press-releases>

*News/Pubs/Press Releases [Selective]*

*No new digest content identified.*

**ICRC** [to 16 Dec 2023]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 16 Dec 2023]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*Press release 13/12/2023*

**[COP28: Urgency, action and funds are missing](#)**

*Press release 11/12/2023*

**[America's Kate Forbes elected President of world's largest humanitarian](#)**

**Institut Pasteur** [to 16 Dec 2023]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 16 Dec 2024]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*News, Blogs*

*Blogs*

**[COP28 agreement: embracing the urgency of the scientific consensus?](#)**

As COP28 ended in Dubai on December 12, 2023, the international community marked a significant step forward in addressing the climate crisis, while acknowledging the urgent need for greater ambition and action. The International Science Council (ISC), its members, Affiliated bodies and partners actively participated, urging policy-makers to seize the momentum and drive ambitious, science-based, sustainable policy solutions to face the existential climate threat.

15.12.2023

*News Press releases*

**[Global Science Leaders ISC and IAP Issue Joint Statement on Protecting the Autonomy of National Academies of Science](#)**

The ISC and IAP are concerned about the autonomy of academies and their members, jeopardizing their capacity to provide valid, ethically sound advice on critical issues affecting humanity and the planet.

15.12.2023

*Blogs*

**[Plans to establish a Pacific academy of sciences forge ahead](#)**

The Pacific scholarly community makes headway with their aspiration to establish a science academy for the Pacific, following the inaugural meeting.

13.12.2023

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>  
*News/Events [Selected]*  
*No new digest content identified.*

**IVAC** [to 16 Dec 2023]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

**[IVAC Participates at Global Digital Health Forum](#)**

December 2023

IVAC faculty and students joined colleagues this month at the Global Digital Health Forum in Bethesda, MD. The forum is the leading public health industry networking and relationship-building opportunity for tech innovators, donors, researchers, government representatives, and implementing organizations working in low- and middle-income countries.

**IVI** [to 16 Dec 2023]

<http://www.ivi.int/>

*IVI News & Announcements*

**[IVI and Gorgas Institute advocate for chikungunya vaccines at global meeting in Panama](#)**

- Over 100 stakeholders from government, research, industry, academia, and global health agencies attended the meeting from December 12-13
- Country representatives from Brazil, Colombia, Dominican Republic, India, Kenya, Panama, Paraguay, and Thailand shared experiences with chikungunya and recent outbreaks

**Johns Hopkins Center for Health Security** [to 16 Dec 2023]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

December 11:

**[Georgetown Center for Global Health Science and Security and Johns Hopkins Center for Health Security Launch New Assessment Manual for Zoonotic Diseases Coordination](#)**

**MSF/Médecins Sans Frontières** [to 16 Dec 2024]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Neglected diseases*

**[MSF joins noma survivors in celebrating inclusion in WHO neglected tropical diseases list](#)**

Press Release 15 Dec 2023

*Palestine*

**[Staggering increase in Israeli attacks against civilians and healthcare in Jenin](#)**

Project Update 15 Dec 2023

**National Academy of Medicine - USA** [to 16 Dec 2023]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academy of Sciences** - USA [to 16 Dec 2023]

<https://www.nationalacademies.org/newsroom?>

*News*

**[New Report Urges Multiagency Action to Support Potentially Transformative Digital Twins Research](#)**

News Release | December 15, 2023

**National Vaccine Program Office** - U.S. HHS [to 16 Dec 2023]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

February 22-23, 2024 (Virtual)

**NIH** [to 16 Dec 2024]

<http://www.nih.gov/>

*News Releases*

**[NIH research identifies opportunities to improve future HIV vaccine candidates](#)**

*Study suggests greater CD8+ T-cell activity may increase HIV immunity*

December 14, 2023

**[Scientists unveil complete cell map of a whole mammalian brain](#)**

NIH-funded atlas characterizes over 32 million cells across the mouse brain.

December 13, 2023

**PATH** [to 16 Dec 2023]

<https://www.path.org/media-center/>

*Newsroom*

**[CEPI and PATH strengthen partnership to accelerate development of vaccines against diseases with epidemic or pandemic potential](#)**

Oslo, Norway; Seattle, Washington, December 14, 2023—The Coalition for Epidemic Preparedness Innovations (CEPI) and PATH today announced a renewed collaboration to accelerate the rapid development of vaccines against emerging infectious diseases, and in support of CEPI's 100 Days Mission, a goal to reduce the time taken to develop safe and effective vaccines against pathogens with epidemic or pandemic potential to 100 days.

Under the terms of the CEPI-PATH Implementing Partnership Agreement, PATH will help CEPI continue to enhance its capacities for project design and management, implementation, coordination and operational oversight. In doing so, PATH will also work with CEPI partners to provide such services that enable the rapid development of vaccines against pathogens with epidemic or pandemic potential, from proof of concept through to licensure.

To this end, PATH will work across multiple CEPI-funded projects, including providing strategic, technical and scientific support for the clinical and manufacturing development process of vaccines, boosting innovative technology development, and facilitating capacity-strengthening initiatives that enhance local resources to help establish or improve research preparedness and emergency evidence generation for future outbreaks...

**Rockefeller Foundation** [to 16 Dec 2023]

<https://www.rockefellerfoundation.org/>

Dec 11 2023 *Press Releases*

**[The Kofi Annan Foundation and The Rockefeller Foundation Announce New Commission to Transform Global Food Security Governance](#)**

*Amid overlapping climate and food crises, the Kofi Annan Commission on Food Security will review and reimagine current systems to reach zero hunger*

**Sabin Vaccine Institute** [to 16 Dec 2023]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 16 Dec 2023]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

15 December 2023

**[Cambodia social protection for people living with HIV](#)**

15 December 2023

**[Responding to gender-based violence through sorority and information](#)**

**UNICEF** [to 16 Dec 2024]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*News note 15 December 2023*

**[2024 looms as 'increasingly bleak' for children affected by armed conflicts and disasters - UNICEF](#)**

<https://www.unicef.org/press-releases/2024-looms-increasingly-bleak-children-affected-armed-conflicts-and-disasters-unicef>

GENEVA, 15 December 2023 – “In the entirety of my more than 25-year career with UNICEF, it is hard to recall a year in which the situation facing children affected by conflict and disaster has been as dire as the one we are currently witnessing. For humanitarian organizations, our work has rarely been as important, and may never have been more...

*Press release 13 December 2023*

**[Children hit ever-harder by Lebanon's unrelenting crises](#)**

<https://www.unicef.org/press-releases/children-hit-ever-harder-lebanons-unrelenting-crises>

BEIRUT, 13 December 2023 – The impact of Lebanon's unrelenting, overlapping crises continues to worsen, increasingly robbing children of their education and forcing many into child labour, as parents struggle with ever-diminishing resources. With data collected in November 2023, UNICEF analysis reveals further deterioration in almost every aspect...

*Statement 13 December 2023*

**[Statement by UNICEF Deputy Executive Director Kitty van der Heijden at the conclusion of COP28](#)**

<https://www.unicef.org/press-releases/statement-unicef-deputy-executive-director-kitty-van-der-heijden-conclusion-cop28>

NEW YORK, 13 December 2023 – “The COP28 climate negotiations generated welcome breakthroughs on both the urgent need to address the root causes of climate change – fossil fuels –



and some glimmers of hope for climate justice for children. Now to have any hope of turning these words into action, we must see a transformative scale up of climate...

*Press release* 13 December 2023

**[Measles cases in Europe and Central Asia skyrocket by 3000 per cent this year compared to last](https://www.unicef.org/press-releases/measles-cases-europe-and-central-asia-skyrocket-3000-cent-year-compared-last)**

<https://www.unicef.org/press-releases/measles-cases-europe-and-central-asia-skyrocket-3000-cent-year-compared-last>

GENEVA, 14 December 2023 – There have been 30,601 confirmed cases of measles in Europe and Central Asia between January and 5 December 2023, up from 909 throughout 2022, marking a 3266 per cent increase in cases of the vaccine-preventable disease, warns UNICEF. Data also point to a more recent worsening trend as the rate of measles cases in Europe...

*Remarks* 12 December 2023

**[UNICEF Executive Director Catherine Russell Remarks at the Launch of UNICEF's 2024 Humanitarian Action for Children appeal](https://www.unicef.org/press-releases/unicef-executive-director-catherine-russell-remarks-launch-unicefs-2024-humanitarian)**

<https://www.unicef.org/press-releases/unicef-executive-director-catherine-russell-remarks-launch-unicefs-2024-humanitarian>

NEW YORK, 12 December 2023 - "Excellencies, partners, friends and supporters of UNICEF, "Thank you so much for joining us today as we launch our 2024 Humanitarian Action for Children appeal. "This appeal comes, as you know, at an especially critical time, with children facing a broad array of intensifying and converging crises ... and with global...

*Press release* 11 December 2023

**[UNICEF appeals for US\\$9.3 billion emergency funding for children living through conflicts and crises in an increasingly hostile world](https://www.unicef.org/press-releases/unicef-appeals-us93-billion-emergency-funding-children-living-through-conflicts-and)**

<https://www.unicef.org/press-releases/unicef-appeals-us93-billion-emergency-funding-children-living-through-conflicts-and>

GENEVA/NEW YORK, 12 December 2023 – In response to an alarming surge in the number of children facing unprecedented humanitarian crises worldwide, UNICEF launched today a US\$9.3 billion emergency funding appeal to reach at least 93.8 million children in 155 countries and territories. In 2024, children across the globe are expected to need life...

**Unitaid** [to 16 Dec 2023]

<https://unitaid.org/>

*Featured News*

15 December 2023

**[Unitaid to support access to monoclonal antibodies in low- and middle-income countries with new call for proposals](#)**

11 December 2023

**[New Child-Friendly Formulation of Rifapentine for Short Course Tuberculosis Prevention Treatment Now Available as Unitaid and IMPAACT4TB Launch an Early Market Access Vehicle](#)**

**Vaccine Equity Cooperative [nee Initiative]** [to 16 Dec 2023]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 16 Dec 2023]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*No new digest content identified.*

**Vaccine Confidence Project** [to 16 Dec 2023]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 16 Dec 2023]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 16 Dec 2023]

<https://wellcome.org/>

*News, Opinion, Reports*

*Research story*

Author: Caesar Atuire

**[Can we measure solidarity?](#)**

13 December 2023

There are often calls for solidarity in times of global health emergencies, but a lack of accountability at the international level. Dr Caesar Atuire’s discovery research project could provide the tools needed to address this.

**The Wistar Institute** [to 16 Dec 2024]

<https://www.wistar.org/news/press-releases>

*Press Releases*

Dec. 13, 2023

**[Wistar Scientists Enhance Cell-Based Therapy to Destroy Solid Tumors](#)**

Dr. Hildegund Ertl and authors use common cholesterol drug to boost therapy

**World Bank** [to 015 Oct 2022]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

**[World Bank Support for Emergency Relief to Gaza](#)**

WASHINGTON, Dec. 12, 2023 — As part of an overall \$35 million package of support, the World Bank announced \$20 million in new financing to provide emergency relief for the affected people of Gaza. This...

Date: December 12, 2023 Type: Press Release

**WFPHA: World Federation of Public Health Associations** [to 16 Dec 2023]

<https://www.wfpha.org/>

*Latest News –*

## **[Looking Back at COP28: Putting Public Health First in Climate Action](#)**

Dec 15, 2023 Hannah Marcus

As COP28 came to a close, it became clearer the importance of focusing on public health to deal effectively with the climate crisis. The World Federation of Public...

## **[World Medical Association \[WMA\]](#)** [to 16 Dec 2023]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

*No new digest content identified.*

## **[World Organisation for Animal Health](#)** [to 16 Dec 2023]

<https://www.oie.int/en/>

*Press Releases, Statements*

*Press Release*

## **[The Quadripartite launches a guide to support countries implement One Health approach](#)**

10 December 2023, Rome/Nairobi/Geneva/Paris – The Quadripartite Collaboration on One Health releases – The guide to Implementing the One Health Joint Plan of Action at National Level to support countries to strengthen their One Health actions.

Recognizing the multitude of risks that a changing climate is having and will continue to have on the health of all life on earth, the launch took place at the United Nations Climate Change Conference (COP28) in Dubai, United Arab Emirates. The launch coincided with the first-ever health day at COP28 as well as a climate and health high-level ministerial meeting.

The Guide is an operational addendum to the 2022 One Health Joint Plan of Action, signalling a strategic objective to country-focused implementation. The guide outlines three pathways – governance, sectoral integration, and evidence and knowledge – and five steps to achieve One Health implementation.

.....

## **[ARM \[Alliance for Regenerative Medicine\]](#)** [to 16 Dec 2023]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

## **[BIO](#)** [to 16 Dec 2023]

<https://www.bio.org/press-releases>

*Press Releases*

## **[BIO Applauds U.N. FAO on Food and Climate Roadmap](#)**

December 14, 2023

The Biotechnology Innovation Organization (BIO) today welcomed the United Nations (U.N.) Food and Agriculture Organization's announcement of a new roadmap outlining how the world can attain global food security by 2050 without breaching the global...

## **[SCOTUS should preserve FDA's "mandated authority" and "scientific and medical expertise" in new case](#)**

December 13, 2023

Today, the Supreme Court announced it will soon weigh in on a case that challenges how the Food and Drug Administration (FDA) regulates mifepristone, a drug it approved almost 25 years ago. BIO interim president and CEO, Rachel King, made the...

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 16 Dec 2023]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 16 Dec 2023]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 16 Dec 2023]

<https://ifpma.org/>

*Selected Press Releases/Statements*

*No new digest announcements identified*

**International Alliance of Patients' Organizations – IAPO** [to 16 Dec 2023]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

**[Kawaldip Sehmi: global champion of patients' rights and the ultimate Expert Patient](#)**

Originally published on the BMJ. Kawaldip Sehmi, chief executive of the International Alliance of Patients' Organizations (IAPO) died unexpectedly. Kawaldip's passion and enthusiasm for his work was inexhaustible and his leadership of IAPO outstanding. He lived, breathed, and skilfully advanced...

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified*

**PhRMA** [to 16 Dec 2023]

<http://www.phrma.org/>

*Press Releases*

**[PhRMA Statement on Proposed March-In Framework](#)**

Dec 6, 2023

Today, Pharmaceutical Research and Manufacturers of America (PhRMA) Deputy Vice President for Public Affairs Megan Van Etten issued the following statement in response to the Biden Administration's proposed

.....

.....

***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

## **AstraZeneca**

Press Releases

Latest

### **[AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data](#)**

12 December 2023

*Building on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases*

## **Bharat Biotech**

Press Releases - No new digest announcements identified.

## **BioCubaFarma – Cuba**

Últimas Noticias - No new digest announcements identified

## **Biological E**

News - No new digest announcements identified

## **BioNTech**

Press Releases

12 December 2023

### **[BioNTech to Inaugurate First African Site on December 18, 2023](#)**

BioNTech will inaugurate its first African site in Kigali, Rwanda, on Monday, December 18<sup>th</sup>, 2023. The inauguration takes place on the occasion of the set-up of the containers for the first manufacturing unit called BioNTainer.

## **Boehringer**

Press Releases - No new digest announcements identified.

## **CanSinoBIO**

News - Website not responding at inquiry

## **CIGB**

Latest News - No new digest announcements identified.

## **Cinnagen**

Recent News - No new digest announcements identified.

## **Clover Biopharmaceuticals - China**

News

Dec 13, 2023

### **[Clover Initiates Phase I Clinical Trial for RSV Vaccine Candidate](#)**

...enrollment of the first participants has been completed in a Phase I first-in-human study evaluating the company's RSV PreF-Trimer subunit vaccine candidate (SCB-1019), which is based on Clover's Trimer-Tag vaccine technology platform...

## **Curevac [Bayer Ag – Germany]**

News - No new digest announcements identified.

## **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

## **GSK**

[Press releases for media](#)

12 December 2023

[Japan's Ministry of Health, Labour and Welfare accepts Arexvy \(RSV vaccine\) regulatory application to prevent RSV disease in adults aged 50-59 at increased risk](#)

11 December 2023

[GSK's Jemperli \(dostarlimab\) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer](#)

**IMBCAMS**, China

[Home](#) - Website not responding at inquiry.

## **Janssen/JNJ**

[Press Releases](#) - No new digest announcements identified

## **Merck**

[News releases](#) - No new digest announcements identified

## **Moderna**

[Press Releases](#)

12/14/2023

[Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company's Investigational Respiratory Syncytial Virus \(RSV\) Vaccine](#)

## **Nanogen**

[News](#) - No new digest announcements identified

## **Novartis**

[News](#) - No new digest announcements identified.

## **Novavax**

[Press Releases](#)

Dec 14, 2023

Statement COVID-19

[Novavax's Updated COVID-19 Vaccine Now Available in Sweden](#)

Dec 14, 2023

Statement COVID-19

[Novavax's Updated COVID-19 Vaccine Now Available in Italy](#)

Dec 11, 2023

Statement COVID-19

[Novavax's Updated COVID-19 Vaccine Now Available as Only Option in Poland](#)

Dec 11, 2023

Statement COVID-19

[Novavax's Updated COVID-19 Vaccine Now Available in Germany](#)

Dec 11, 2023  
Statement COVID-19

## [Novavax's Updated COVID-19 Vaccine Now Available in Austria](#)

### **Pfizer**

[Recent Press Releases](#) - No new digest announcements identified.

### **R-Pharm**

<https://rpharm-us.com/index.php>  
[No news or media page identified]

### **Sanofi Pasteur**

[Press Releases](#)  
December 15, 2023

[Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness \(rhodesiense\) found in East and Southern Africa](#)

### **Serum Institute of India**

[NEWS & ANNOUNCEMENTS](#) - No new digest announcements identified

### **Sinopharm/WIBPBIBP**

[News](#) - No new digest announcements identified [English translation function not operating]

### **Sinovac**

[Press Releases](#) - No new digest announcements identified.

### **SK Biosciences**

[Press Releases](#) - No new digest announcements identified.

### **Takeda**

[Newsroom](#) - No new digest announcements identified.

### **Valneva**

[Press Releases](#) - No new digest announcements identified.

### **Vector State Research Centre of Virology and Biotechnology**

[Home](#) - Website not responding [404 error]

### **WestVac Biopharma**

[Media](#) - No new digest announcements identified.

### **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]  
[Website](#) [No News/Announcements page identified]

.....  
.....

**[Contents \[click to move among sections\]](#)**

:: [Milestones, Perspectives](#)

:: [WHO](#)



[:: Organization Announcements](#)

[:: Journal Watch](#)

[:: Pre-Print Servers](#)

.....

.....

### **Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 14, 2023 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 25, Number 12: E855-915 Dec 2023

<https://journalofethics.ama-assn.org/issue/health-and-loneliness>

#### ***Belonging, Placement, and Turfing***

The language of "placement" is key in health care organizations' admissions and discharge planning policies and practices. Where patients are thought to belong has substantial clinical and ethical heft in the everyday operations of the US health services sector. Turfing is generally regarded as an inappropriate reference to patients whose needs and vulnerabilities prompt us to want to make them someone else's responsibility. Turfing can happen in inpatient settings when one care team looks to divert responsibility for a patient's care to another team, in outpatient settings when clinicians refuse to take care of, say, patients insured by Medicare or Medicaid, and in discharge planning to rehabilitation or skilled care facilities. This theme issue investigates clinical and ethical criteria for determining what it means to be a person who belongs somewhere under a clinician's watch in health care.

### **American Journal of Human Genetics**

Dec 07, 2023 Volume 110 Issue 12 p1987-2120

<https://www.cell.com/ajhg/current>

[Reviewed earlier]

### **American Journal of Infection Control**

December 2023 Volume 51 Issue 12 p1295-1454

<http://www.ajicjournal.org/current>

[New issue; No digest content identified]

**American Journal of Preventive Medicine**

December 2023 Volume 65 Issue 6 p953-1202

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

**American Journal of Public Health**

December 2023 113(12)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**

Volume 109 (2023): Issue 6 (Dec 2023)

<https://www.ajtmh.org/view/journals/tpmd/109/4/tpmd.109.issue-6.xml>

*Articles*

**[Did COVID-19 or COVID-19 Vaccines Influence the Patterns of Dengue in 2021? An Exploratory Analysis of Two Observational Studies from North India](#)**

Upinder Kaur, et al.

DOI: <https://doi.org/10.4269/ajtmh.23-0418>

Page(s): 1290–1297

**Annals of Internal Medicine**

November 2023 Volume 176, Issue 11

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 324 November 2023

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/324/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 16 Dec 2023)

[No new digest content identified]

**BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 16 Dec 2023)

[No new digest content identified]

**BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 16 Dec 2023)

**[Vaccine acceptance, determinants, and attitudes toward vaccine among people experiencing homelessness: a systematic review and meta-analysis](#)**

*COVID-19 has caused millions of deaths globally, with vulnerable populations such as people experiencing homelessness (PEH) at higher risk. This systematic review and meta-analysis aims to identify the prevalence...*

Authors: Dung Anh Nguyen, Habib Olatunji Alagbo, Toka Adel Hassan, Leonardo D. Mera-Lojano, Esraa Osama Abdelaziz, Nguyen Pham Nguyen The, Abdelrahman M. Makram, Omar M. Makram, Randa Elsheikh and Nguyen Tien Huy

Citation: BMC Infectious Diseases 2023 23:880

Content type: Research Published on: 15 December 2023

**[Prevention, testing, and treatment interventions for hepatitis B and C in refugee populations: results of a scoping review](#)**

*Refugees are at higher risk for hepatitis B (HBV) and hepatitis C (HCV), but often face unique healthcare barriers to vaccination, testing, and treatment. This scoping review aimed to identify and characterize...*

Authors: Ankeeta Saseetharan, Lindsey Hiebert, Neil Gupta, Françoise Nyirahabihirwe, Innocent Kamali and John W. Ward

Citation: BMC Infectious Diseases 2023 23:866

Content type: Research Published on: 9 December 2023

**BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmethics/content>

(Accessed 16 Dec 2023)

[No new digest content identified]

**BMC Medicine**

<http://www.biomedcentral.com/bmcmmed/content>

(Accessed 16 Dec 2023)

[No new digest content identified]

**BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 16 Dec 2023)

**[A scoping review of the reasons for and approaches to non-uptake of pertussis and influenza vaccinations in pregnant women in the United Kingdom and Ireland](#)**

*Pertussis and influenza cause significant morbidity and mortality in pregnancy and the neonatal period. Maternal vaccination in pregnancy would reduce harm, but low vaccine uptake is a concern. This scoping review...*

Authors: Stephanie Ann McCarron, Declan Terence Bradley and Nigel David Hart

Citation: BMC Pregnancy and Childbirth 2023 23:857

Content type: Research Published on: 12 December 2023

**BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 16 Dec 2023)

**[Institutional trust is a distinct construct related to vaccine hesitancy and refusal](#)**

*Vaccine hesitancy is driven by a heterogeneous and changing set of psychological, social and historical phenomena, requiring multidisciplinary approaches to its study and intervention. Past research has brought...*

Authors: Sekoul Krastev, Oren Kraiden, Zoua M. Vang, Fernanda Pérez-Gay Juárez, Elizaveta Solomonova, Maya J. Goldenberg, Daniel Weinstock, Maxwell J. Smith, Esme Dervis, Dan Pilat and Ian Gold

Citation: BMC Public Health 2023 23:2481

Content type: Research Published on: 12 December 2023

### **[COVID-19 vaccination strategies in settings with limited rollout capacity: a mathematical modelling case study in Sierra Leone](#)**

*COVID-19 vaccine coverage in low- and middle-income countries continues to be challenging. As supplies increase, coverage is increasingly becoming determined by rollout capacity.*

Authors: Gizem Mayis Bilgin, Kamalini Lokuge, Ernest Jabbe, Syarifah Liza Munira and Kathryn Glass

Citation: BMC Public Health 2023 23:2466

Content type: Research Published on: 11 December 2023

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 16 Dec 2023)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

December 2023 - Volume 28 - 6

<https://ebm.bmj.com/content/28/6>

[Reviewed earlier]

### **BMJ Global Health**

December 2023 - Volume 8 - 12

<https://gh.bmj.com/content/8/12>

*Analysis*

### **[Traditional, complementary and integrative healthcare: global stakeholder perspective on WHO's current and future strategy](#)** (2 December, 2023)

Tido von Schoen-Angerer, Raj Kumar Manchanda, Iva Lloyd, Jon Wardle, Janka Szöke, Iracema Benevides, Natalia Sofia Aldana Martinez, Festus Tolo, Ton Nicolai, Cristal Skaling-Klopstock, Tabatha Parker, Dwi Linna Suswardany, Robbert van Haselen, Jianping Liu

*Commentary*

### **[Ending TB means responding to socially produced vulnerabilities of all genders](#)** (9 December, 2023)

Beate Ringwald, Amon Ashaba Mwiine, Jeremiah Chikovore, Goodman Makanda, Jerry Amoah-Larbi, Kerry A. Millington, Katherine C. Horton

### **[Negotiating the media's role during pandemics: recommendations for future preparedness](#)** (6 December, 2023)

Nina Acharya, Sarah Hess, Hannah Kuchler, Jesse Lafontaine, Mia Malan, Tanvi Rai, Helene-Mari van der Westhuizen

*Original research*

**[Authorship inequalities in global health research: the IeDEA Southern Africa collaboration](#)** (16 December, 2023)

Veronika W Skrivankova, Stefanie Hossmann, Morna Cornell, Marie Ballif, Carole Dupont, Jacqueline Huwa, Konstantinos Seintaridis, Thokozani Kalua, Gilles Wandeler, Reshma Kassanjee, Andreas D Haas, Karl-Gunter Technau, Lukas Fenner, Nicola Low, Mary-Ann Davies, Matthias Egger

**[Improved vaccine coverage for First Nations children receiving first dose on-reserve: a retrospective cohort study in western Canada](#)** (12 December, 2023)

Shannon E MacDonald, Bonny Graham, Keith D King, Li Huang, Lawrence W. Svenson, Gregg Nelson

**[COVID-19 vaccination implementation in 52 African countries: trajectory and implications for future pandemic preparedness](#)** (6 December, 2023)

Oghenebrume Wariri, Muhammed Olanrewaju Afolabi, Christinah Mukandavire, Yauba Saidu, Obe Destiny Balogun, Sidy Ndiaye, Emmanuel A Okpo, Terna Nomhwange, Olalekan A Uthman, Beate Kampmann

**Bulletin of the Atomic Scientists**

November 2023

<https://thebulletin.org/magazine/2023-11/>

[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 101(12); 2023 Dec 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/449832/>

*Research*

**[Comparative performance of national civil registration and vital statistics systems: a global assessment](#)**

Lene Mikkelsen, Jessica Hooper, Tim Adair, Azza Badr, Alan D Lopez

Bull World Health Organ. 2023 Dec 1; 101(12): 758–767. Published online 2023 Oct 19.

doi: 10.2471/BLT.22.289033

PMCID: PMC10680112

*Lessons from the Field*

**[Polio outbreak response, Yemen](#)**

Ibrahim Abdulllah Beshr, Mohammed Sadeq Beshr, Hibah Abdulqader Al-Qubati

Bull World Health Organ. 2023 Dec 1; 101(12): 808–812. Published online 2023 Oct 12.

doi: 10.2471/BLT.23.290122

PMCID: PMC10680107

**Cell**

Dec 07, 2023 Volume 186 Issue 25 p5433-5674

<https://www.cell.com/cell/current>

*Featured Article*

**[Next-generation primate genomics: New genome assemblies unlock new questions](#)**

Genevieve Housman, Jenny Tung

Nonhuman primates provide unique evolutionary and comparative insight into the human phenotype. Genome assemblies are now available for nearly half of the species in the primate order,

expanding our understanding of genetic variation within and between species and making important contributions to evolutionary biology, evolutionary anthropology, and human genetics.

### **Child Care, Health and Development**

Volume 49, Issue 6 Pages: 941-1111 November 2023

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 114, Issue 6 Pages: 1143-1387 December 2023

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

### **Clinical Therapeutics**

December 2023 Volume 45 Issue 12 p1161-1298

<http://www.clinicaltherapeutics.com/current>

[New issue; No digest content identified]

### **Clinical Trials**

Volume 20 Issue 6, December 2023

<https://journals.sagepub.com/toc/ctja/20/6>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 16 Dec 2023]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 134 November 2023

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/134/suppl/C>

[Reviewed earlier]

### **The CRISPR Journal**

Volume 6, Issue 5 / October 2023

<https://www.liebertpub.com/toc/crispr/6/5>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

## **Current Medical Research and Opinion**

Volume 39, Issue 11 2023

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

## **Current Opinion in Infectious Diseases**

December 2023 - Volume 36 - Issue 6

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

## **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 16 Dec 2023]

[No new digest content identified]

## **Developing World Bioethics**

Volume 23, Issue 4 Pages: 293-377 December 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

*ORIGINAL ARTICLES*

Open Access

[\*\*Reasons for and insights about HPV vaccination refusal among ultra-Orthodox Jewish mothers\*\*](#)

[Rivka Zach](#), [Miriam Ethel Bentwich](#)

Pages: 300-311

First Published: 06 October 2022

## [\*\*A proposal for an international Code of Conduct for data sharing in genomics\*\*](#)

[Amal Matar](#), [Mats Hansson](#), [Santa Slokenberga](#), [Adam Panagiotopoulos](#), [Gauthier Chassang](#), [Olga Tzortzatou](#), [Kärt Pormeister](#), [Elias Uhlin](#), [Antonella Cardone](#), [Michael Beauvais](#)

Pages: 344-357

First Published: 21 October 2022

## [\*\*Evolving capacity of children and their best interests in the context of health research in South Africa: An ethico-legal position\*\*](#)

[Melodie Labuschaigne](#), [Safia Mahomed](#), [Ames Dhai](#)

Pages: 358-366

First Published: 13 November 2022

## **Development in Practice**

Volume 33, Issue 8, 2023

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

## **Development Policy Review**

Volume 41, Issue S6 December 2023

<https://onlinelibrary.wiley.com/toc/14677679/current>

***Special Issue: Aid in the Pacific***



[New issue; No digest content identified]

### **Disaster Medicine and Public Health Preparedness**

Volume 16 - Issue 6 - December 2022

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 47, Issue 4 Pages: 847-1173 October 2023

<https://onlinelibrary.wiley.com/toc/14677717/2023/47/4>

[Reviewed earlier]

### **EMBO Reports**

Volume 24 Issue 12 6 December 2023

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 29, Number 12—December 2023

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

### **Epidemics**

Volume 45 December 2023

<https://www.sciencedirect.com/journal/epidemics/vol/45/suppl/C>

*Review article Open access*

[\*\*Modelling outbreak response impact in human vaccine-preventable diseases: A systematic review of differences in practices between collaboration types before COVID-19\*\*](#)

James M. Azam, Xiaoxi Pang, Elisha B. Are, Juliet R.C. Pulliam, Matthew J. Ferrari  
Article 100720

### **Epidemiology and Infection**

Volume 151 - 2023

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 45, Issue 6 Pages: 1-50 November–December 2023

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Passing demands in autism research :: Women missing in phase I trials***

[Reviewed earlier]

## **Ethics & International Affairs**

Volume 37 - Issue 3 - Fall 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

## **Ethics, Medicine and Public Health**

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

## **The European Journal of Public Health**

Volume 33, Issue 6, December 2023

<https://academic.oup.com/eurpub/issue/33/6>

*Vaccination*

### **[Exploring missed opportunities for influenza vaccination and influenza vaccine co-administration patterns among Italian older adults: a retrospective cohort study](#)**

Alexander Domnich and others

European Journal of Public Health, Volume 33, Issue 6, December 2023, Pages 1183–1187,

<https://doi.org/10.1093/eurpub/ckad155>

### **[Estimated number of reported vaccine-preventable disease cases averted following the introduction of routine vaccination programs in Sweden, 1910–2019](#)**

Leah J Martin and others

European Journal of Public Health, Volume 33, Issue 6, December 2023, Pages 1188–1193,

<https://doi.org/10.1093/eurpub/ckad169>

### **[Health status, healthcare use and child MMR vaccination coverage in Travellers according to their environmental and living conditions in Nouvelle-Aquitaine, France, 2019–2022](#)**

Aude Mondeilh and others

European Journal of Public Health, Volume 33, Issue 6, December 2023, Pages 1194–1199,

<https://doi.org/10.1093/eurpub/ckad175>

## **Expert Review of Vaccines**

Vol 22 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

## **Foreign Affairs**

January/February 2024 Volume 103, Number 1

<https://www.foreignaffairs.com/issues/2023/103/1>

[Reviewed earlier]

## **Forum for Development Studies**

Volume 50, 2023 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

### **Genetics in Medicines**

Volume 25, Issue 12 December 2023

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/12>

[New issue; No digest content identified]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 16 Dec 2023]

[No new digest content identified]

### **Global Health Action**

Volume 16, Issue 1 (2023)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 11, No. 5 October 30, 2023

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 16 Dec 2023]

[No new digest content identified]

### **Global Public Health**

Volume 18, Issue 1 (2023)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 16 Dec 2023]

[No new digest content identified]

### **Health and Human Rights**

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

***Special Section: Economic Inequality and the Right to Health***

## **Health Economics, Policy and Law**

Volume 18 - Special Issue 4 - October 2023

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

***SPECIAL ISSUE: On the roof top of health policy change***

[Reviewed earlier]

## **Health Policy and Planning**

Volume 38, Issue 10, December 2023

<https://academic.oup.com/heapol/issue/38/10>

*Original Articles*

**[The political economy of financing traditional vaccines and vitamin A supplements in six African countries](#)**

Justice Nonvignon and others

Health Policy and Planning, Volume 38, Issue 10, December 2023, Pages 1154–1165,

<https://doi.org/10.1093/heapol/czad079>

*Reviews*

**[A scoping review on integrated health campaigns for immunization in low- and middle-income countries](#)**

Syeda Tahmina Ahmed and others

Health Policy and Planning, Volume 38, Issue 10, December 2023, Pages 1198–1224,

<https://doi.org/10.1093/heapol/czad082>

## **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 16 Dec 2023]

[No new digest content identified]

## **Human Gene Therapy**

Volume 34, Issue 21-22 / November 2023

<https://www.liebertpub.com/toc/hum/34/21-22>

[Reviewed earlier]

## **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

## **Immunity**

Dec 12, 2023 Volume 56 Issue 12 p2665-2856

<https://www.cell.com/immunity/current>

*Featured Article*

**[RNA vaccines: A transformational advance](#)**

Brian D. Brown, Anthony S. Fauci, Yasmine Belkaid, Miriam Merad

Vaccines have stemmed many infectious diseases, but when SARS-CoV-2 emerged, traditional vaccine development would not have been fast enough. This year's Nobel Prize in Physiology or Medicine recognizes work that enabled the rapid development of mRNA vaccines, which halted the COVID-19 pandemic. The feat was a product of basic biological insights coupled with technological innovations, which have transformed vaccine design.

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 16 Dec 2023]

[No new digest content identified]

**Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 16 Dec 2023]

[No new digest content identified]

**International Health**

Volume 15, Issue 6, November 2023

<https://academic.oup.com/inthealth/issue/15/6>

*ORIGINAL ARTICLES*

**[Factors associated with COVID-19 vaccine hesitancy among healthcare workers in Cameroon and Nigeria: a web-based cross-sectional study](#)**

Jerry Brown Aseneh and others

International Health, Volume 15, Issue 6, November 2023, Pages 702–714,

<https://doi.org/10.1093/inthealth/ihad013>

**International Human Rights Law Review**

Volume 12 (2023): Issue 1 (Jul 2023)

<https://brill.com/view/journals/hrlr/12/1/hrlr.12.issue-1.xml>

*Table of Contents*

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol. 10 No. 9 (2023): September 2023

<https://www.ijcmph.com/index.php/ijcmph/issue/view/104>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 52, Issue 5, October 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

## **International Journal of Human Rights in Healthcare**

Volume 16 Issue 3 2023

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3>

*Table of contents*

[Reviewed earlier]

## **JAMA**

December 12, 2023, Vol 330, No. 22, Pages 2135-2224

<https://jamanetwork.com/journals/jama/currentissue>

*Viewpoint*

### **[Health Professionals and War in the Middle East](#)**

Matthew K. Wynia, MD, MPH

JAMA. 2023;330(22):2155-2156. doi:10.1001/jama.2023.24247

In this Viewpoint, the author examines whether health care professionals have any responsibilities to speak out about the conflict in the Middle East.

## **JAMA Health Forum**

December 2023, Vol 4, No. 12

<https://jamanetwork.com/journals/jama-health-forum/issue>

[New issue; No digest content identified]

## **JAMA Pediatrics**

December 2023, Vol 177, No. 12, Pages 1247-1364

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

## **JBI Evidence Synthesis**

November 2023 Volume 73 Issue 5 p797-966

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

## **Journal of Adolescent Health**

November 2023 Volume 73 Issue 5 p797-966

<https://www.jahonline.org/current>

[Reviewed earlier]

## **Journal of Artificial Intelligence Research**

Vol. 78 (2023)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

## **Journal of Community Health**

Volume 48, issue 6, December 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-6>

[Reviewed earlier]

**Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

June 18, 2023 Vol 6, No 06 (2023)

<https://www.cmro.in/index.php/jcmro/issue/view/68>

[Reviewed earlier]

**Journal of Development Economics**

Volume 166 January 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/166/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 18 Issue 5, December 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

October 2023 - Volume 77 - 10

<https://jech.bmj.com/content/77/10>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 16, Issue 3 Pages: 259-413 September 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 19, Issue 2 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 34, Number 4, November 2023

<https://muse.jhu.edu/issue/51329>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 25, issue 6, December 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-6>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 21, 2023 \_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 228, Issue 5, 1 September 2023

<https://academic.oup.com/jid/issue/228/5>

[Reviewed earlier]

**Journal of International Development**

Volume 35, Issue 8 Pages: 2251-2685 November 2023

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

**Journal of Medical Ethics**

December 2023 - Volume 49 - 12

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 10, Issue 3 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**The Journal of Pediatrics**

Volume 264 January 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/264/suppl/C>

*Discussion*

**[Worldwide Newborn Screening and Early Immunizations: Aligning Advances in Preventive Pediatrics](#)**

Francisca Grob, Isaac Odame, Guy Van Vliet

Article 113732

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 16 Dec 2023]

[No new digest content identified]

**Journal of Public Health Management & Practice**

January/February 2024 - Volume 30 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>



[Reviewed earlier]

### **Journal of Public Health Policy**

Volume 44, issue 4, December 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-4>

[New issue; No digest content identified]

### **Journal of the Royal Society – Interface**

December 2023 Volume 20 Issue 209

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

### **Journal of Travel Medicine**

Volume 30, Issue 7, October 2023

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

### **Journal of Virology**

Volume 97 • Number 11 • November 2023

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Dec 16, 2023 Volume 402 Number 10419 p2265-2394

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

#### **[The promise of genetic therapies in sickle cell disease](#)**

The Lancet

*Seminar*

#### **[Malaria](#)**

Jeanne Rini Poespoprodjo, et al.

*Summary*

Malaria is resurging in many African and South American countries, exacerbated by COVID-19-related health service disruption. In 2021, there were an estimated 247 million malaria cases and 619 000 deaths in 84 endemic countries. Plasmodium falciparum strains partly resistant to artemisinins are entrenched in the Greater Mekong region and have emerged in Africa, while Anopheles mosquito vectors continue to evolve physiological and behavioural resistance to insecticides. Elimination of Plasmodium vivax malaria is hindered by impractical and potentially toxic antirelapse regimens. Parasitological diagnosis and treatment with oral or parenteral artemisinin-based therapy is the mainstay of patient management. Timely blood transfusion, renal replacement therapy, and restrictive fluid therapy can improve survival in severe malaria. Rigorous use of intermittent preventive treatment in pregnancy and infancy and seasonal chemoprevention, potentially combined with pre-erythrocytic vaccines endorsed by WHO in 2021 and 2023, can substantially reduce malaria morbidity. Improved surveillance, better access to effective treatment, more labour-efficient vector control, continued drug development, targeted mass drug

administration, and sustained political commitment are required to achieve targets for malaria reduction by the end of this decade.

*Countdown*

**[The 2023 report of the Lancet Countdown on health and climate change: the imperative for a health-centred response in a world facing irreversible harms](#)**

Marina Romanello, et al.

The Lancet Countdown is an international research collaboration that independently monitors the evolving impacts of climate change on health, and the emerging health opportunities of climate action. In its eighth iteration, this 2023 report draws on the expertise of 114 scientists and health practitioners from 52 research institutions and UN agencies worldwide to provide its most comprehensive assessment yet.

**The Lancet Child & Adolescent Health**

Jan 2024 Volume 8 Number 1 p1-84

<https://www.thelancet.com/journals/lanchi/issue/current>

*Editorial*

**[The future of children's human rights: a call for peace](#)**

The Lancet Child & Adolescent Health

2023 marks the 75th anniversary of the Universal Declaration of Human Rights (UDHR) and 34th anniversary of the UN Convention of the Rights of the Child (UNCRC). These documents recognise that “all human beings are born free and equal in dignity and rights” and that children are distinct, independent rights holders. Against a backdrop of children's rights increasingly being eroded by poverty, water insecurity, climate change, displacement, conflict, and other crises, these anniversaries are celebrated with a heavy heart. As world leaders prepare for the Human Rights 75 high-level meeting on Dec 11–12, 2023, they must unanimously reinvigorate commitments to the UDHR and UNCRC...

**Lancet Digital Health**

Dec 2023 Volume 5 Number 12 e848-e932

<https://www.thelancet.com/journals/landig/issue/current>

[New issue; No digest content identified]

**Lancet Global Health**

Jan 2024 Volume 12 Number 1 e1-e169

<https://www.thelancet.com/journals/langlo/issue/current>

*Comment*

**[World Society for Pediatric Infectious Diseases calls for action to ensure fair prices for vaccines](#)**

Fiona M Russell, et al. on behalf of the World Society of Pediatric Infectious Diseases

... The COVID-19 pandemic has imposed tremendous economic and social challenges worldwide, and concerns over vaccine access and affordability are rising. The scientific community has learned much on vaccine development during the pandemic, but there remain profound and widening gaps for equitable vaccine access. Despite the lifesaving potential of the new respiratory syncytial virus vaccine for infants or through maternal vaccination in low-income countries, it is unlikely that these children will be protected for many years. Vaccine price should not be a barrier to the introduction or sustainability of immunisation programmes.

Therefore, the World Society for Pediatric Infectious Diseases calls for fair pricing for all vaccines to ensure that they are global public goods. We ask governments and international organisations to act urgently to protect the lives of present and future generations via global, equitable access to affordable vaccines through a comprehensive approach ([panel](#)).

*Panel*

**Recommended actions by stakeholders for achieving fair vaccine prices for low-income and middle-income countries (LMICs)**

*Pharmaceutical companies*

- Commit to fair, equitable pricing strategies for vaccines, considering the socioeconomic context of all LMICs, and publish pricing by income status of countries
- Facilitate technology transfer and knowledge sharing to enable local production, local fill and finish technology, and reduce dependence on imports

*Governments and international organisations*

- Negotiate affordable pricing structures en bloc with regional states and pharmaceutical companies, promoting transparency and fair competition, and commit to publishing pricing by income status
- Explore alternative procurement strategies and promote regional cooperation and support efforts, such as the Pan American Health Organization's Revolving Fund to Access Vaccines and UNICEF's Pacific Vaccine Independence Initiative
- Support technology transfer and capacity-building initiatives to enhance local vaccine production, such as the WHO-supported mRNA technology hub in South Africa

*Research and development funders*

- Increase investments in research and development of vaccines, specifically targeting diseases prevalent in LMICs
- Encourage partnerships between academic institutions, pharmaceutical companies, and international organisations to foster vaccine research and innovation, and improve affordability

*Global health initiatives*

- Strengthen international collaborations to address vaccine inequity, and include all countries with low availability of public health funds irrespective of World Bank income classifications
- Advocate for policies and mechanisms that promote equitable vaccine access, including flexibilities

*Series*

*The People's Voice Survey on Health System Performance*

**[Population confidence in the health system in 15 countries: results from the first round of the People's Voice Survey](#)**

Margaret E Kruk, et al.

*The People's Voice Survey on Health System Performance*

**[Health system quality and COVID-19 vaccination: a cross-sectional analysis in 14 countries](#)**

Catherine Arsenault, et al.

**Lancet Infectious Diseases**

Nov 2023 Volume 23 Number 11 p1207-1322, e455-e505

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

## **Lancet Public Health**

Dec 2023 Volume 8 Number 12 e905-e1042

<https://www.thelancet.com/journals/lanpub/issue/current>

*Health Policy*

**[Adding new childhood vaccines to China's National Immunization Program: evidence, benefits, and priorities](#)**

Haijun Zhang, et al.

## **Lancet Respiratory Medicine**

Nov 2023 Volume 11 Number 11 p945-1034, e89-e95

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

## **Maternal and Child Health Journal**

Volume 27, issue 12, December 2023

<https://link.springer.com/journal/10995/volumes-and-issues/27-12>

[Reviewed earlier]

## **Medical Decision Making (MDM)**

Volume 43 Issue 7-8, October-November 2023

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

## **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 101, Issue 3 Pages: 637-998 September 2023

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

## **Molecular Therapy**

Dec 06, 2023 Volume 31 Issue 12 p3357-3612

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

## **Nature**

Volume 624 Issue 7991, 14 December 2023

<https://www.nature.com/nature/volumes/622/issues/7990>

### ***Brain maps***

In this week's issue, researchers working as part of the BRAIN Initiative Cell Census Network (BICCN) present nine papers that map the entire mouse brain in unprecedented detail. Three papers by Hongkui Zeng, Xiaowei Zhuang, Evan Macosko and colleagues describe the transcriptomic and spatial cell atlases of the whole mouse brain, depicting the molecular signatures, spatial organization, and cell-cell interactions of thousands of cell types. (A related paper published earlier by Xiao Wang and co-workers also probes the cell type architecture in the brain.)

A pair of papers by Edward Callaway, Joseph Ecker, Zhigang He and colleagues examine the links between the identity of neurons and where they extend their axons. And across three papers, Bing

Ren, Joseph Ecker and co-workers examine the epigenetic landscape of the mouse brain, looking at regulatory elements in various cell types. Finally, Karthik Shekhar, Joshua Sanes and colleagues use single-cell RNA sequencing data from 17 vertebrate species to probe the evolution of cell types in the retina

### **Nature Biotechnology**

Volume 41 Issue 12, December 2023

<https://www.nature.com/nbt/volumes/41/issues/12>

*Perspective* 26 Oct 2023

#### **[Expanding access to CAR T cell therapies through local manufacturing](#)**

Shortages of CAR T cells should be alleviated by distributed manufacturing, according to Elsallab and Maus.

Magdi Elsallab, Marcela V. Maus

### **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 16 Dec 2023)

[No new digest content identified]

### **Nature Genetics**

Volume 55 Issue 12, December 2023

<https://www.nature.com/ng/volumes/55/issues/12>

[Reviewed earlier]

### **Nature Human Behaviour**

Volume 7 Issue 11, November 2023

<https://www.nature.com/nathumbehav/volumes/7/issues/11>

[Reviewed earlier]

### **Nature Medicine**

Volume 29 Issue 12, December 2023

<https://www.nature.com/nm/volumes/29/issues/12>

*Article* Open Access 27 Nov 2023

#### **[Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial](#)**

A four-arm cluster-randomized trial testing the effects of a low cash incentive, a high cash incentive, a health message and a placebo on COVID-19 vaccine uptake in villages in rural Ghana demonstrated highest uptake with a low cash incentive.

Raymond Duch, Edward Asiedu, Philip Clarke

*Article* Open Access 04 Dec 2023

#### **[Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results](#)**

In a prespecified 3-year analysis of the KEN SHE trial, single-dose HPV vaccination was shown to be well tolerated and provided durable protection against cervical HPV infection in Kenyan women aged 15–20 years.

Ruanne V. Barnabas, Elizabeth R. Brown, Torin T. Schaafsma

### **Nature Reviews Drug Discovery**

Volume 22 Issue 11, November 2023

<https://www.nature.com/nrd/volumes/22/issues/11>

[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 24 Issue 12, December 2023

<https://www.nature.com/nrg/volumes/24/issues/12>

[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 23 Issue 11, November 2023

<https://www.nature.com/nri/volumes/23/issues/11>

[Reviewed earlier]

### **New England Journal of Medicine**

December 14, 2023 Vol. 389 No. 24

<https://www.nejm.org/toc/nejm/medical-journal>

*Original Articles*

#### **[Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults](#)**

E. Wilson and Others

#### **[Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age](#)**

A. Hsiao and Others

*Editorials*

#### **[Continued Progress in the Development of Safe and Effective RSV Immunizations](#)**

A.C. Cohn and A.J. Hall

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 16 Dec 2023]

[No new digest content identified]

### **Pediatrics**

Volume 152, Issue 5 November 2023

<https://publications.aap.org/pediatrics/issue/152/4>

[Reviewed earlier]

### **PharmacoEconomics**

Volume 41, issue 11, November 2023

<https://link.springer.com/journal/40273/volumes-and-issues/41-11>

[Reviewed earlier]

## **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 16 Dec 2023)

[No new digest content identified]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 16 Dec 2023)

[No new digest content identified]

## **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 16 Dec 2023)

### **[Facing the escalating burden of dengue: Challenges and perspectives](#)**

Gathsaurie Neelika Malavige, Peter Sjö, Kavita Singh, Jean-Michel Piedagnel, Charles Mowbray, Sergio Estani, Steven Chee Loon Lim, Andre M. Siquierra, Graham S. Ogg, Laurent Fraisse, Isabela Ribeiro

Review | published 15 Dec 2023 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002598>

## **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 16 Dec 2023)

[No new digest content identified]

## **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 16 Dec 2023)

[No new digest content identified]

## **PLoS One**

<http://www.plosone.org/>

[Accessed 16 Dec 2023]

### **[Determinants of human papillomavirus vaccine hesitancy among Lebanese parents](#)**

Ramia Zakhour, Hani Tamim, Farah Faytrouni, Maha Makki, Rayan Hojeij, Lama Charafeddine

Research Article | published 13 Dec 2023 PLOS ONE

<https://doi.org/10.1371/journal.pone.0295644>

### **[Socioeconomic inequalities in vaccine uptake: A global umbrella review](#)**

Amber Sacre, Clare Bambra, Josephine M. Wildman, Katie Thomson, Natalie Bennett, Sarah Sowden, Adam Todd

Research Article | published 13 Dec 2023 PLOS ONE

<https://doi.org/10.1371/journal.pone.0294688>

## **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 16 Dec 2023]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

December 12, 2023 vol. 120 no. 50

<https://www.pnas.org/toc/pnas/120/49>

[New issue; No digest content identified]

### **PNAS Nexus**

Volume 2, Issue 10, October 2023

<https://academic.oup.com/pnasnexus/issue/2/10>

[Reviewed earlier]

### **Prehospital & Disaster Medicine**

Volume 38 - Issue 5 - October 2023

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

### **Preventive Medicine**

Volume 175 October 2023

<https://www.sciencedirect.com/journal/preventive-medicine/vol/175/suppl/C>

[New issue; No digest content identified]

### **Proceedings of the Royal Society B**

29 November 2023 Volume 290 Issue 2011

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

### **Public Health**

Volume 223 Pages e1-e16, 1-256 (October 2023)

<https://www.sciencedirect.com/journal/public-health/vol/223/suppl/C>

[Reviewed earlier]

### **Public Health Ethics**

Volume 16, Issue 2, July 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Genomics**

2023, Vol. 26, No. 1

<https://karger.com/phg/issue/26/1>

[Reviewed earlier]



## **Public Health Reports**

Volume 138 Issue 5, September/October 2023

<https://journals.sagepub.com/toc/phrg/138/5>

[Reviewed earlier]

## **Qualitative Health Research**

Volume 33 Issue 13, November 2023

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

## **Research Ethics**

Volume 19 Issue 4, October 2023

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

## **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 16 Dec 2023]

[No new digest content identified]

## **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

12 Dec 2023

[Maintaining measles elimination status in Colombia during outbreak control, 2019](#)

Original research | Spanish |

12 Dec 2023

[External quality control program in infectious diseases screening at laboratories and blood banks in Latin America: an analysis of the past 5 years](#)

Original research | English |

## **Risk Analysis**

Volume 43, Issue 11 Pages: 2147-2399 November 2023

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 16 Dec 2023]

[Reviewed earlier]

## **Science**

Volume 382| Issue 6676| 15 Dec 2023

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

### **Science and Engineering Ethics**

Volume 29, Issue 6 December 2023

<https://link.springer.com/journal/11948/volumes-and-issues/29-6>

[Reviewed earlier]

### **Science Translational Medicine**

Volume 15| Issue 726| 13 Dec 2023

<https://www.science.org/toc/stm/current>

*Viewpoint*

#### **[Data-driven science and diversity in the All of Us Research Program](#)**

BY Geoffrey S. Ginsburg, Joshua C. Denny, Sheri D. Schully

13 Dec 2023

The NIH's All of Us research program hosts genomic and phenotypic data to be collected from one million diverse participants in the United States.

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 16 Dec 2023]

[No new digest content identified]

### **Social Science & Medicine**

Volume 339 December 2023

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/339/suppl/C>

[New issue; No digest content identified]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 16 Dec 2023]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 44, issue 5, October 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-5>

[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 55 September–October 2023

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/55/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 28, Issue 11 Pages: i-iv, 839-869 November 2023

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

## Vaccine

Volume 41, Issue 51 Pages 7581-7640 (12 December 2023)

<https://www.sciencedirect.com/journal/vaccine/vol/41/issue/50>

*Research article* Open access

### **[Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned](#)**

Ynke Larivière, Trésor Zola Matuvanga, Gwen Lemey, Bernard Isekah Osang'ir, ... Patrick Mitashi  
Pages 7587-7597

*Research article* Open access

### **[Strengthening immunization programs through innovative sub-national public-private partnerships in selected provinces in the Democratic Republic of the Congo](#)**

Patrick Banza Mpiongo, Jerry Kibanza, Francis Kambol Yav, Didier Nyombo, ... Aimé Cikomola  
Pages 7598-7607

*Research article* Open access

### **["I'd do it for my baby": Lessons learned from qualitative research on COVID-19 vaccination among pregnant women in Côte d'Ivoire](#)**

Danielle Naugle, Natalie Tibbels, Abdul Dosso, William Benie, Marjorie Nana  
Pages 7626-7631

## Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 16 Dec 2023]

*Latest Articles [Selected]*

*Open Access Review*

### **[The Governance of Childhood Vaccination Services in Crisis Settings: A Scoping Review](#)**

by [Nada Abdelmagid](#), et al.

Vaccines 2023, 11(12), 1853; <https://doi.org/10.3390/vaccines11121853> - 14 Dec 2023

*Abstract*

The persistence of inadequate vaccination in crisis-affected settings raises concerns about decision making regarding vaccine selection, timing, location, and recipients. This review aims to describe the key features of childhood vaccination intervention design and planning in crisis-affected settings and investigate how the governance of childhood vaccination is defined, understood, and practised. We performed a scoping review of 193 peer-reviewed articles and grey literature on vaccination governance and service design and planning. We focused on 41 crises between 2010 and 2021. Following screening and data extraction, our analysis involved descriptive statistics and applying the governance analysis framework to code text excerpts, employing deductive and inductive approaches. Most documents related to active outbreaks in conflict-affected settings and to the mass delivery of polio, cholera, and measles vaccines. Information on vaccination modalities, target populations, vaccine sources, and funding was limited. We found various interpretations of governance, often implying hierarchical authority and regulation. Analysis of governance arrangements suggests a multi-actor yet fragmented governance structure, with inequitable actor participation, ineffective actor collaboration, and a lack of a shared strategic vision due to competing priorities and accountabilities. Better documentation of vaccination efforts during emergencies,

including vaccination decision making, governance, and planning, is needed. We recommend empirical research within decision-making spaces.

## Value in Health

December 2023 Volume 26 Issue 12 p1675-1812

<https://www.valueinhealthjournal.com/current>

[New issue; No digest content identified]



### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)



## ***Pre-Print Servers***

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 16 Dec 2023]

*Selected Research*

*Research Article* metrics AWAITING PEER REVIEW

**[Understanding evidence ecosystems: What influences the production, translation, and use of modeled evidence in Burkina Faso, Nigeria, India, and Kenya?](#)** [version 1; peer review: awaiting peer review]

Ali Sié, Habibou Fofana, Moubassira Kagoné, Moussa Ouédraogo, Obinna E. Onwujekwe, Chinyere O. Mbachu, Maulik Chokshi, Latha Chilgod, Tushar Mokashi, Arun B. Nair, Peter Muriuki, Abeba Taddese, Leah Ewald, Apoorva Handigol

Peer Reviewers Invited

Funder

Bill and Melinda Gates Foundation

PUBLISHED 13 Dec 2023

This study sought to document and understand facilitators and barriers to producing, translating, and using modeled evidence in decision-making in Burkina Faso, Nigeria, India, and Kenya. We explored researcher-decision-maker engagement mechanisms as key facilitators of evidence use, with a focus on knowledge brokers and boundary organizations.

## **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 16 Dec 2023]

[Filter: All articles]

**[Protect or prevent? A practicable framework for the dilemmas of COVID-19 vaccine prioritization](#)**

Raghu Arghal, Harvey Rubin, Shirin Saedi Bidokhti, Saswati Sarkar

medRxiv 2023.12.10.23299100; doi: <https://doi.org/10.1101/2023.12.10.23299100>

## Abstract

Determining COVID-19 vaccination strategies presents many challenges in light of limited vaccination capacity and the heterogeneity of affected communities. Who should be prioritized for early vaccination when different groups manifest different levels of risks and contact rates? Answering such questions often becomes computationally intractable given that network size can exceed millions. We obtain a framework to compute the optimal vaccination strategy within seconds to minutes from among all strategies, including highly dynamic ones that adjust vaccine allocation as often as required, and even with modest computation resources. We then determine the optimal strategy for a large range of parameter values representative of various US states, countries, and case studies including retirement homes and prisons. The optimal is almost always one of a few candidate strategies, and, even when not, the suboptimality of the best among these candidates is minimal. Further, we find that many commonly deployed vaccination strategies, such as vaccinating the high risk group first, or administering second doses without delay, can often incur higher death rates, hospitalizations, and symptomatic counts. Our framework can be easily adapted to future variants or pandemics through appropriate choice of the compartments of the disease and parameters.

## **Resources to Aid Ethical Review of Clinical Studies: Gaps and Opportunities**

Merle-Marie Pittelkow, Daniel Strech

doi: <https://doi.org/10.1101/2023.12.13.23299842>

### *Abstract*

Research Ethics Committees (RECs) review the ethical, legal, and methodological standard of clinical research. However, complying with all requirements and professional expectations while maintaining the necessary scientific and ethical standards can be challenging for applicants and members of the REC alike. There is a need for easily accessible and clear guidelines and resources to help medical researchers and REC members navigate the legal and ethical requirements and the process of their review. We employed an explorative search for resources on the websites of relevant stakeholders including 12 national umbrella associations (six German-language and six English-language), three English-language international umbrella associations, and 16 national REC's of major university hospitals (eight German- and eight English-language). We mapped the identified resources onto the guiding principles of ethical clinical research and 35 related checkpoints. To describe the content of the resources we conducted a thematic analysis. We extracted a total of 233 resources, including templates (n = 134, 58.5%), guidelines/recommendations (n = 62, 26.6%), checklists (n = 23, 9.9%), tools (n = 5, 2.2%), flowcharts (n = 5, 2.2%), glossaries (n = 3, 1.3%), and one (0.4%) software program. We extracted 101 German and 132 English resources created between 2004 and 2023. The majority (n = 204; 87.6%) could be assigned to one checkpoint. The remaining 29 (12.5%) resources were considered unspecific (e.g., a checklist which documents to be submitted for a German drug trial). The specific resources are discussed per checkpoint. While much support is available for some aspects such as participant information and informed consent forms, it is lacking in other areas such as study design, analysis, and biometrics. More support should be provided in these areas to ensure that research projects are methodologically sound. A more detailed analysis of the quality of available resources could help identify other areas of need.

## **Synthetic Health Data Can Augment Community Research Efforts to Better Inform the Public During Emerging Pandemics**

Anish Prasanna, Bocheng Jing, George Plopper, Kristina Krasnov Miller, Jaleal Sanjak, Alice Feng, Sarah Prezek, Eshaw Vidyaprakash, Vishal Thovarai, Ezekiel Maier, Avik Bhattacharya, Lama Naaman, Holly Stephens, Sean Watford, W. John Boscardin, Elaine Johanson, Amanda Lienau  
medRxiv 2023.12.11.23298687; doi: <https://doi.org/10.1101/2023.12.11.23298687>

### *Abstract*

The COVID-19 pandemic had disproportionate effects on the Veteran population due to the increased prevalence of medical and environmental risk factors. Synthetic electronic health record

(EHR) data can help meet the acute need for Veteran population-specific predictive modeling efforts by avoiding the strict barriers to access, currently present within Veteran Health Administration (VHA) datasets. The U.S. Food and Drug Administration (FDA) and the VHA launched the precisionFDA COVID-19 Risk Factor Modeling Challenge to develop COVID-19 diagnostic and prognostic models; identify Veteran population-specific risk factors; and test the usefulness of synthetic data as a substitute for real data. The use of synthetic data boosted challenge participation by providing a dataset that was accessible to all competitors. Models trained on synthetic data showed similar but systematically inflated model performance metrics to those trained on real data. The important risk factors identified in the synthetic data largely overlapped with those identified from the real data, and both sets of risk factors were validated in the literature. Tradeoffs exist between synthetic data generation approaches based on whether a real EHR dataset is required as input. Synthetic data generated directly from real EHR input will more closely align with the characteristics of the relevant cohort. This work shows that synthetic EHR data will have practical value to the Veterans' health research community for the foreseeable future.

### **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

***We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.***

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 16 Dec 2023]

*Selected Research*

*Open Letter Open Access*

**[REVISED-Invisibility in global health: A case for disturbing bioethical frameworks](#)**

[version 2; peer review: 3 approved with reservations]

Arsenii Alenichev, et al

*Abstract*

In recent years, the global health community has increasingly reported the problem of 'invisibility': aspects of health and wellbeing, particularly amongst the world's most marginalized and impoverished people, that are systematically overlooked and ignored by people and institutions in relative positions of power.

It is unclear how to realistically manage global health invisibility within bioethics and other social science disciplines and move forward. In this letter, we reflect on several case studies of invisibility experienced by people in Brazil, Malaysia, West Africa and other transnational contexts. Highlighting the complex nature of invisibility and its interconnectedness with social, political and economic issues and trends, we argue that while local and targeted interventions might provide relief and comfort locally, they will not be able to solve the underlying causes of invisibility.

Building from the shared lessons of case study presentations at an Oxford-Johns Hopkins Global Infectious Disease Ethics Collaborative (GLIDE), we argue that in dealing with an intersectional issue such as invisibility, twenty-first century global health bioethics could pursue a more 'disturbing' framework, challenging the narrow comforting solutions which take as a given the sociomaterial inequalities of the status quo. We highlight that comforting and disturbing bioethical frameworks should not be considered as opposing sides, but as two approaches working in tandem in order to achieve the internationally set global health milestones of providing better health and wellbeing for everyone. Insights from sociology, anthropology, postcolonial studies, history, feminist studies and other styles of critical reasoning have long been disturbing to grand narratives of people and their

conditions. To rediscover the ethos of the WHO Alma Ata Declaration—a vision of “health for all by the year 2000”—these thinking tools will be necessary aids in developing cooperation and support beyond the narrow market logic that dominates the landscape of contemporary global health.

*Study Protocol Open Access*

**[REVISED-MOSAIC: A cohort study of human mpox virus disease](#)** [version 3; peer review: 2 approved]

Elise Pesonel , et al.

*Abstract*

Background

Human mpox is a viral disease caused by an Orthopoxvirus, human mpox virus (hMPXV), typically causing fever and a rash. Mpox has historically been endemic to parts of Central and West Africa, with small numbers of imported cases reported elsewhere, but starting May 2022 an unprecedented global outbreak caused by clade I Ib hMPXV was reported outside traditionally endemic countries. This prompted the initiation of MOSAIC, a cohort study implemented in Europe and Asia that aims to describe clinical and virologic outcomes of PCR-confirmed hMPXV disease, including those who receive antiviral therapy. The focus of this article, however, is on describing the study protocol itself with implementation process and operational challenges.

\* \* \* \*

### ***Think Tanks***

**Brookings** [to 16 Dec 2023]

<http://www.brookings.edu/>

*Research*

**[Assessing CMMI’s proposals on Medicaid payment for cell and gene therapies](#)**

*Health Care Policy*

Matthew Fiedler, Richard G. Frank

December 12, 2023

**Center for Global Development** [to 16 Dec 2023]

<https://www.cgdev.org/>

*All Research [Selected]*

*POLICY PAPERS*

**[Projections of Eligibility and Transition Trajectories up to 2040: Implications for Gavi’s Next Strategic Period and Beyond](#)**

Morgan Pincombe et al.

December 14, 2023

The prevailing fiscal outlook alongside broader shifts in the health landscape have important implications for countries’ eligibility for support from Gavi, the Vaccine Alliance. Current projections are similar to pre-COVID estimates, but the cohort of transitioning countries face more challenging

**Chatham House** [to 16 Dec 2023]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [to 16 Dec 2023]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 16 Dec 2023]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**Kaiser Family Foundation** [to 16 Dec 2023]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

*No new digest content identified.*

**McKinsey Global Institute** [to 16 Dec 2023]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 16 Dec 2023]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 16 Dec 2023]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 16 Dec 2023]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*Journal Article*

**[Geospatially Clustered Low COVID-19 Vaccine Rates Among Adolescents in Socially Vulnerable US Counties](#)**

This study aimed to test for geospatial clustering of COVID-19 vaccine rates among adolescents aged 12-17 across the U.S. counties and to compare these clustering patterns by sociodemographic characteristics.

Dec 14, 2023

Sophie R. Alphonso, Marcus R. Andrews, Seann D. Regan, Alyssa Shishkov, Jonathan H. Cantor, Tiffany M. Powell-Wiley, Kosuke Tamura

**Urban Institute** [to 16 Dec 2023]

<https://www.urban.org/publications>



## [New Research Publications - Selected](#)

*Research Report*

### [Do No Harm Guide: Collecting, Analyzing, and Reporting Gender and Sexual Orientation Data](#)

December 4, 2023

**World Economic Forum** [to 16 Dec 2023]

<https://agenda.weforum.org/press/>

*Media*

### [Digital Tools for Health Workers 'Can Stem Growing Health Crises'](#)

News 11 Dec 2023

.....  
.....

## **Public Consultations/Call for Inputs/Call for Papers**

### [Concept paper on the development of an addendum to the Guideline on clinical development of vaccines on clinical trials for vaccines for immunocompromised individuals \(PDF/185.17 KB\)](#)

EMA/CHMP Reference number: /453562/2023

First published: 03/11/2023 **Consultation dates: 01/11/2023 to 01/01/2024**

*Problem statement*

The Guideline on clinical evaluation of vaccines EMEA/CHMP/VWP/164653/05 Rev. 1 (3) does not provide detailed guidance on the design of clinical trials to assess the safety, immunogenicity and efficacy of vaccines in immunocompromised individuals. There is a need to provide some guidance on potentially suitable sub-populations of immunocompromised individuals for trials to improve the extrapolation of the findings to other sub-populations. Moreover, to consider designing studies in immunocompromised individuals that not only document whether immune responses are lower than in the immunocompetent population but also give some indication of alternative doses and/or regimens that could provide adequate levels of protection against infectious diseases.

Comments should be provided using this [EUSurvey form](#). For any technical issues, please contact the [EUSurvey Support](#).

### [Concept paper on the revision of the Non-clinical and Clinical Module of the influenza vaccines guideline \(PDF/177.49 KB\)](#)

EMA

First published: 31/10/2023 **Consultation dates: 01/11/2023 to 30/01/2024**

*Summary/Problem statement [Excerpt]*

The proposed guideline will replace Guideline on influenza vaccines, non-clinical and clinical modules (EMA/CHMP/VWP/457259/2014).

...The current guideline text addresses collection of vaccine effectiveness data for approved vaccines by season. The collection of reliable data, especially brand-specific data, has proven difficult even within countries with high quality influenza disease surveillance. There is a need to rediscuss the feasibility of the current recommendations, while still acknowledging the utility of such data to detect unexpected effectiveness signals.

Overall, there is some degree of urgency to revise the guideline on non-clinical and clinical development of influenza vaccines. In particular, to add sections relevant to the development of

mRNA-based influenza vaccines and to reflect on how lessons learned from the COVID-19 pandemic could be relevant to the development of influenza vaccines, including those intended only for pandemic usage.

Comments should be provided using this EUSurvey [form](#). For any technical issues, please contact the [EUSurvey Support](#)

\* \* \* \* \*  
\* \* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \* \*  
\* \* \* \* \*